Owner Investor / Financier Operator Developer Offtaker
Lonza is a Swiss-based global contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries. The company provides development and manufacturing services across biologics and small molecules, including bioconjugates and antibody–drug conjugates (ADCs), as well as cell and gene therapies. Its capabilities span highly potent active pharmaceutical ingredients (HPAPIs), microbial and mammalian platforms, and sterile drug product activities.
Lonza’s offering covers the full lifecycle from early development to commercial supply, including formulation, process and analytical development, drug substance manufacturing (such as monoclonal antibodies, payload–linker components, and other intermediates), conjugation services, and aseptic fill–finish with options like lyophilization. The company operates major sites in Switzerland (including Visp, Stein, and Basel) and a broader global network in Europe, North America, and Asia, supporting clinical and commercial programs for customers ranging from emerging biotechs to large biopharma.
chemXplore tracks 7 projects involving Lonza, of which 2 are active.
Besides these 2, the record holds 5 completed projects.
Closest to start-up first.
The 5 that are completed, on hold or cancelled are in the record. See all 7 in chemXplore →
Board chair Thomas Leysen will retire; shareholders will vote on Richard Ridinger at an Extraordinary General Meeting on 19 Oct 2026.
The new cGMP filling line will enhance bioconjugate handling and create 115 jobs by 2027, expanding end-to-end ADC manufacturing capabilities and supporting clinical and commercial supply.
The new cGMP line in Visp is operational, with first batches in April 2023. It supports clinical and commercial needs, enhancing end-to-end solutions and complementing recent site expansions.
The expansion includes two new manufacturing suites, enhancing capabilities for clinical and commercial supply, and increasing process, analytical development, and quality control capacity.
The CHF 500M facility, set for 2026 completion, will enhance end-to-end drug product manufacturing, leveraging existing infrastructure and focusing on sustainability with a photovoltaic roof.
Investment in new filling line and expanded Drug Product Services in Stein and Basel will enhance capabilities for various drug modalities, creating over 70 jobs and supporting clinical and commercial stages.
active all projects
